ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics.
William Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019. He will be based in Basel, report to Severin Schwan, Roche Group CEO and become a member of the Corporate Executive Committee.
Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.
Merck today announced the appointment of Jasper Bos as the new Managing Director of its strategic corporate venture capital arm M Ventures.
Bergenbio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, has announced the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
In February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology spoke with Günter Huhle, Head of Johnson & Johnson Innovation JLABS EMEA, about Johnson & Johnson‘s approach to open innovation and its tremendous global innovation network, currently comprising ten incubators and over 420 companies that have collectively raised over US$10bn in growth capital.
Hox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.
Oxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
Zelluna Immunotherapy has announced the appointment of Geir Christian Melen as chief financial officer (CFO).
Big Pharma’s interest in R&D on anti-infectives declined when other areas like oncology began offering higher returns. A few biotechs mirror pharma (Basilea, Idorsia and Polyphor), but could stay hidden gems.